Would you be so kind as to pass that "next front line molecule" stuff on to the insurance companies who will fight tooth and nail to make sure that title is given to generic Gleevec for as long as humanly possible.
The fight for the front line will be a difficult one regardless of the fact that Ponatinib is most likely as we speak best in class.